CL1 A Novel Method for Calculating Prevalence of Multiple Sclerosis in Australia  by Palmer, A.J. & Hitchens, P.L.
vitality. Australian values differed from those reported elsewhere. CONCLUSIONS:
This research provides an Australian algorithm for cost-utility analyses using the
SF-6D. DCEs are a valuable alternative approach to the time trade-off or standard
gamble. The explicit consideration of design principles is a major strength of the
study reported here.Morework, however, is required to identify howDCEs can best
be employed to estimate utility weights for health states.
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OBJECTIVES: To determine the prevalence of Multiple Sclerosis (MS) in Australia in
2010 using a novel method based on Australia-wide prescription data for MS-spe-
cific disease modifying agents. The results obtained were validated against the
results of the Australian Bureau of Statistics (ABS) survey of disability, ageing and
carers (SDAC) of 27,600 households and 200 non-private dwellings conducted in
2009, and against MS Society registered client numbers. METHODS: We obtained
the total number of scripts for medications that are used exclusively for the treat-
ment of MS written in Australia for the period January-December 2010 from the
Australian Pharmaceutical Benefit Services (PBS). Numbers of scripts dispensed
were obtained by state for Betaferon, Avonex, Copaxone, Rebif 44, and Tysabri.
Additional data, not captured in the PBS prescription data, was supplied by Biogen
on the number of prescriptions for Tysabri issued in the same period under the
Special Access Service arrangement. The percentage of MS patients using these
medications (42-46%) was taken from state-specific surveys of MS Society clients.
To estimate the total number of persons with MSwe divided the annual number of
scripts dispensed by 12 and adjusted for penetration of MS immuno-modifiers by
state. Sensitivity analysis was performed. RESULTS: The prevalence of MS in Aus-
tralia in 2010 calculated using the prescription method was 21,283 people (95.5 per
100,000). This compared to 21,200 (95.2/100,000) obtained from the ABS-SDAC sur-
vey of 2009, and 19,889 (89.3/100,000) using MS Society client numbers. Prevalence
increased with increasing latitude. Results were sensitive to the percentage of
people with MS assumed to be treated with disease modifying agents.
CONCLUSIONS: Nation-wide prescription data for MS-specific disease modifying
agents is a novel method for calculating prevalence of MS that generates results
that are similar to other potentially more resource intensive methods for calculat-
ing MS prevalence.
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OBJECTIVES: To find out the usefulness of Days Lost due to Disability (DLD) in
calculating the burden of adverse drug reactions due to diclofenac.METHODS: The
studywas conducted in 2010 for the cohort dispensedwith diclofenac tablets in one
pharmacy at South India. Those who were co-prescribed with other anti-inflam-
matory agents and having serious co-morbidity were excluded from the study. The
study subjects (18-65 years) were instructed to report any suspected side effects on
their next visit or through phone call. DLD is calculated similar to Years Lost Due to
Disability (YLD) by multiplying the occurrence of Adverse Drug Reactions (ADRs),
its duration and disability weight. DW was calculated in an analogue scale of 0-1
were 0 is perfect health. Naranjo Causality assessmentwas used to qualify ADRs on
it probability. RESULTS: In a total of 1000 prescription of 943 patients’ 34 types of
ADRs were identified with a total score of 561. The most occurring ADRs were on
gastrointestinal system (48%). Abdominal pain occurred for 107 times. There were
only 34 cases of peptic ulcers but it was themost disabling ADRwith a DLD of 0.078.
There were only few cases of acute renal failure (DLD 0.012) and Steven-Johnson
Syndrome (DLD 0.013); still they scored a significant DLD as the outcomewasmore
damaging. DLD can be calculated only in recovered patients. DLD is a useful indi-
cator of assessing the burden of ADRs managed in different health care settings
with varying resources. CONCLUSIONS:DLD could represent the burden of ADR on
health. It considers the occurrence, duration and reduction in health due to ADRs.
So DLD could be a useful tool in assessing the outcome of ADRs.
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OBJECTIVES: Limited evidence is available regarding pharmacist managed antico-
agulation clinic (PMAC) in the Southeast Asian region where there is marked dif-
ference in terms of care model, genetic composition and patient demographics.
This study aimed at comparing the anticoagulation clinic managed by the phar-
macist with physician advisory and the usual medical care provided in Kuala Lum-
pur Hospital (KLH) in terms of anticoagulation control and adverse outcomes.
METHODS: A 2302 bedded government tertiary referral hospital in Malaysia. A
6-month retrospective cohort study of the effectiveness of 2 models of anticoagu-
lation care, the pharmacistmanaged anticoagulation clinic (PMAC) and usualmed-
ical clinic (UMC) in KLH was conducted, where a random number generator was
used to recruit patients. The UMC patients received standard medical care where
they aremanaged by rotationalmedical officers in the Physicians’ Clinic. As for the
PMAC with physician advisory, the pharmacist will counsel and review the pa-
tients Internationalised Normalization Ratio (INR) at each clinic visit and also ad-
just the patients’ warfarin dose accordingly. Patients are referred to physicians if
immediate attention is required. The main therapeutic outcome is time in thera-
peutic range both actual and expanded TTR and thromboembolic and bleeding
complications. RESULTS: Each of the PMAC and usual medical care recruited 92
patients, which totals to 184 patients. The patient demographics in terms of age,
race and indication of treatment were comparable. At the end of the 6 months
follow-up, patients in the PMAC group had significantly higher actual-TTR (65.1%
vs. 48.3%; P0.05) compared to those in usualmedical care group. Rates of bleeding
incidenceswere 6.5 versus 21.7 events per 100 person-years for the PMAC andUMC
groups, respectively. CONCLUSIONS: PMAC provided a significantly better antico-
agulation care than usual medical care. The PMAC with physician advisory has
been successfully implemented in Kuala Lumpur Hospital.
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OBJECTIVES: To examine the drug switching events among non-steroidal anti-
inflammatory drugs (NSAIDs) users and co-medication with gastro-protective
drugs (GPDs) as an early determinant of dissatisfaction from gastrointestinal (GI)
adverse events. METHODS: The Taiwan Longitudinal Health Insurance Database
2000 during 1997 to 2008 was used to identify patients with newly diagnosis of RA
(ICD-9-CM: 714.0-714.3) or OA (715.0-715.9) in 1998-2007 to allow for one or more
follow-up year. For each patient, the intervals were identified by any gaps of 30 or
more days between drug dispensing coverage. Intervals were classified into 3 cat-
egories: traditional NSAID (tNSIAD), preferential (pC2SI: meloxicam, etodolac,
nabumetone and nimesulide) or specific COX-2 selective inhibitor (COXIB: cele-
coxib, rofecoxib and etoricoxib). For each patient-interval, the event of switching
from one of the 3 categories to another was considered as the dissatisfaction with
early GI adverse events. Intervals with less than 60 days of NSAID dispensing were
excluded. Consideringwith/without GPDs, these intervalswere divided into 7med-
ication groups: tNSAID alone, COXIB alone, or pC2SI alone, tNSAID with hista-
mine-2 antagonist (H2RA), proton pump inhibitor (PPI), COXIB, or pC2SI. The Cox
regressions with covariates including age, gender, number of prior GI hospitaliza-
tion, co-medication, comorbidity were used to estimate the hazard ratios (HRs) of
drug switching among medication groups. RESULTS: There were 271,683 intervals
identified from97,834 patients. Given no prior GI history, patients in tNSIADH2RA
and tNSIADPPI were significantly less likely to switch (HR0.63, 95%CI0.61-
0.65); HR0.82, 95%CI0.72-0.93) than the tNSAID only. The HRs for drug switching
in COXIB, tNSIAD COXIB, pC2SI and tNSIADpC2SI, however, were 8.04, 6.64,
10.353 and 9.93 (all p value0.0001), respectively. CONCLUSIONS: Combination of
H2RA or PPI was shown less likely to switch than tNSAID alone. These results
suggest that H2RA or PPI could be an acceptable augmentation in clinical practice
for reducing potential GI adverse events.
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OBJECTIVES: Statins, which vary considerably in their lipid-lowering potencies, are
prescribed at non-equivalent doses in Australia. This study sought to estimate the
effects of non-equivalent prescribing on low-density lipoprotein cholesterol
(LDL-C) levels and cardiovascular risk for the four most commonly prescribed
statins. METHODS: The weighted average daily doses (WADDs) of pravastatin,
simvastatin, atorvastatin and rosuvastatin prescribed in 2011, in Australia were
sourced from Pharmaceutical Benefit Scheme (PBS) data. Dose-specific, LDL-C
modifying potencies of these four statins were derived from the meta-analysis by
Law et al (BMJ 2003). The relationship between reduction in LDL-C achieved by
statin therapy and reduction in cardiovascular risk was derived from the recent
meta-regression by the Cholesterol Treatment Trialists’ Collaboration (Lancet
2010). This showed that for every 1mmol/L reduction in LDL-C, the relative risk for
a major cardiovascular (coronary and/or stroke) event was 0.78 (95%CI 0.76-0.80).
RESULTS: In 2011 the WADDs for pravastatin, simvastatin, atorvastatin and rosu-
vastatinwere 38.4mg, 36.3mg, 34.2mg and 14.9mg, respectively. The corresponding
expected reductions in LDL-C were 29.0%, 37.3%, 48.2% and 44.9%. Assuming a
pre-treatment LDL-C of 4.13mmol/L (the threshold for treatment recommended in
international guidelines), these lipid changes translated to expected reductions in
the risk of a major cardiovascular event of 26.3%, 33.9%, 43.8% and 40.0% for prav-
astatin, simvastatin, atorvastatin and rosuvastatin, respectively. CONCLUSIONS:
In Australia, atorvastatin and rosuvastatin are prescribed at higher LDL-C-reducing
doses than pravastatin and simvastatin, and hence would be more effective at
reducing cardiovascular risk. The advantages of atorvastatin and rosuvastatin will
be further enhanced when their acquisition prices fall in 2012.
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